ReviewSeminars in perinatology2026
Cochlear implantation for sensorineural hearing loss caused by neonatal hyperbilirubinemia.
Review in Seminars in perinatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundHyperbilirubinemia is a leading cause of sensorineural hearing loss (SNHL) and auditory neuropathy spectrum disorder (ANSD) in neonates. This review synthesizes current evidence to describe key aspects of cochlear implantation (CI) in neonates with hyperbilirubinemia.
objectiveTo educate a wide audience on the pathophysiology, audiometric challenges, hearing aid trial considerations, optimal timing, and expected outcomes of CI in neonates with bilirubin-induced hearing loss.
methodsA comprehensive review was conducted on PubMed and Cochrane databases to explore current clinical practice guidance for evaluating neonates with hyperbilirubinemia for CI.
resultsBilirubin has neurotoxic effects on the auditory pathway in neonates, making it challenging to have strict audiometric criteria for CI. Hearing trials serve the dual purpose of diagnosis and therapy for infants with hearing loss and can identify strong candidates for CI or, conversely, exclude children who may not benefit from CI. Optimal timing of CI balances diagnostic certainty with earlier intervention. Provider counseling is crucial in preparing families for expected outcomes after CI, which are generally favorable, but can vary among infants depending on factors such as interdisciplinary care coordination.
conclusionAudiologic monitoring, careful CI decision-making, and realistic outcome counseling optimize candidate selection and care for neonates with bilirubin-induced hearing loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.